|
Orthologous residues
|
|
DNA‑PK (human): T2609‑p, DNA‑PK (mouse): T2605‑p, DNA‑PK (rat): T2603‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Disease tissue studied:
bone cancer
|
|
Relevant cell lines - cell types - tissues:
CHO (fibroblast), HeLa (cervical), HSF (fibroblast), U2OS (bone cell)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
hamster, human
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ATR (human)
|
co-immunoprecipitation, pharmacological activator of upstream enzyme, genetic transfer of dominant-negative enzyme, siRNA inhibition of enzyme, phospho-antibody, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
ionizing radiation
|
|
|
|
increase
|
|
|
UV
|
|
|
|
increase
|
|
|
wortmannin
|
UV
|
|
|
no effect upon treatment-induced increase
|
|
|
caffeine
|
UV
|
|
|
inhibit treatment-induced increase
|
|
|
siRNA
|
UV
|
|
|
no effect upon treatment-induced increase
|
ATM siRNA
|
|
siRNA
|
UV
|
|
|
inhibit treatment-induced increase
|
ATR siRNA
|
|